Provided herein is a method for removing uremic toxins from blood is provided. The method includes exposing blood to iron-based metal-organic frameworks; and allowing the metal-organic frameworks to bind a least one uremic toxin in the blood.

Supported catalysts include a solid support, a metal-ligand complex tethered to a surface of the solid support through at least two surface reactive moieties of the metal-ligand complex, and a conformationally stable molecular pore defined between the metal-ligand complex and the surface of the solid support. The metal-ligand complex includes a catalytic metal center, such as a transition metal, coordinated with multiple monodentate ligands, a multidentate ligand, or a combination thereof. The ligands include a tethering portion that is terminated by a surface reactive moiety tethered to the surface of the solid support by a surface interaction. By tailoring the tethering portion, a volume of the molecular pore may be provided that is selective and suitable for a chosen reactant or a chosen reaction type.

A catalyst is provided having: (a) at least one multimetallic salt; and (b) at least one organic acid, wherein the at least one multimetallic salt to the at least one organic acid weight ratio is in the range of 1:0.01-1:0.5. A process is also provided for the preparation of the catalyst and for the preparation of the multimetallic salt.

Nanoparticles that can be used as hydrosilylation and dehydrogenative silylation catalysts. The nanoparticles have at least one transition metal with an oxidation state of 0, chosen from the metals of columns 8, 9 and 10 of the periodic table, and at least one carbonyl ligand, preferably a silicide.

Disclosed are a pincer-type ligand having a structurally rigid acridane structure and a metal complex consisting of the pincer-type ligand and a metal bound to each other, and exhibiting high reactivity and stability during a variety of bonding activation reactions. T-shaped complexes can be prepared from .sup.acriPNP(4,5-bis(diisopropylphosphino)-2,7,9,9-tetramethyl-9H-acridin-10-ide), which is a pincer-type PNP ligand having an acridane structure, and metal complexes, which can be structurally rigid and thus exhibit excellent reactivity and stability based on minimized structural change thereof, can be prepared by introducing an acridane structure into the backbone thereof. The PNP ligand is structurally stable and has novel chemical properties, as compared to conventional similar ligands, and thus can be utilized in a wide range of catalytic reactions and material chemistry.

The present invention is directed to curable compositions comprising: (a) a polyene; (b) a polythiol, present in an amount greater than 10 percent by weight based on the total weight of components (a) and (b) in the curable composition; and (c) a catalytic component consisting essentially of: (i) a metal compound; and (ii) a compound different from (i) that catalyzes an addition reaction between an ethylenically unsaturated compound and a thiol. The catalytic composition is essentially free of vanadium compounds. In the curable composition, either (1) both components (i) and (ii) of the catalytic composition (c) are added as a single package to (a) and/or (b); or (2) component (i) and/or (ii) of the catalytic composition (c) is added in separate packages to (a) and/or (b) of the curable composition. The present invention is further drawn to coated articles and methods of extending pot life of a curable composition.

A method of making an M-N—C catalyst is disclosed. The method includes the steps of (a) contacting an N-doped carbon support with a basic solution that includes a metal salt, whereby the N-doped carbon support is metalated by the metal cation of the metal salt to form one or more chelated metal-nitrogen complexes (MN.sub.x species); and (b) subsequently contacting the metalated N-doped carbon support with an acid, whereby the one or more MN.sub.x species formed on the N-doped carbon support in step (a) remain intact while other species are removed. The resulting composition may be catalytically activated by heat treating the composition. The activated catalyst may be used to catalyze a wide range of chemical reactions.

Aspects of the present disclosure generally relate to copper-containing bimetallic structures, to processes for producing the copper-containing bimetallic structure, and to uses of the copper-containing bimetallic structures as, e.g., catalysts. In an aspect, a process for forming a bimetallic structure is provided. The process includes forming a mixture comprising a first precursor and a second precursor, the first precursor comprising copper, the second precursor comprising a phosphine. The process further includes introducing a third precursor with the mixture to form the bimetallic structure, the third precursor comprising a Group 8-10 metal, the bimetallic structure comprising copper (Cu), the Group 8-10 metal (M), phosphorous (P), and nitrogen (N), the bimetallic structure having the formula (Cu).sub.a(M).sub.b(P).sub.c(N).sub.d, wherein a molar ratio of a:b is from about 1:99 to about 99:1, and a molar ratio of a:(c+d) is from about 500:1 to about 1:1.

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/CuI. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

A compound capable of coordinating with a metal includes a chemical structure as shown in claim 1, in which: EPD represents a group having an electron pair donor atom; B and B′ are each independently an aryl group, a heteroaryl group, an alkenyl group, or alkynyl group, or B and B′ form a spirocyclic group; and R.sub.1, R.sub.2, and R.sub.3 are selected from various substituents.